Key result
A novel MYL3 missense mutation (p.V79I) caused hypertrophic cardiomyopathy with 40% penetrance, presenting with low expressivity and late onset.
Why the study?
What are the phenotypic characteristics, penetrance, and expressivity of the novel MYL3 p.V79I mutation in hypertrophic cardiomyopathy?
Observational (n=310)
What are the phenotypic characteristics, penetrance, and expressivity of the novel MYL3 p.V79I mutation in hypertrophic cardiomyopathy?
The novel MYL3 p.V79I mutation causes hypertrophic cardiomyopathy characterized by low expressivity and late onset.
Hypertrophic cardiomyopathy (HCM) is caused by mutations in genes encoding sarcomere proteins. Mutations in MYL3, encoding the essential light chain of myosin, are rare and have been associated with sudden death. Both recessive and dominant patterns of inheritance have been suggested. We studied a large family with a 38-year-old asymptomatic HCM-affected male referred because of a murmur. The patient had HCM with left ventricular hypertrophy (max WT 21 mm), a resting left ventricular outflow gradient of 36 mm Hg, and left atrial dilation (54 mm). Genotyping revealed heterozygosity for a novel missense mutation, p.V79I, in MYL3. The mutation was not found in 300 controls, and the patient had no mutations in 10 sarcomere genes. Cascade screening revealed a further nine heterozygote mutation carriers, three of whom had ECG and/or echocardiographic abnormalities but did not fulfil diagnostic criteria for HCM. The penetrance, if we consider this borderline HCM the phenotype of the p.V79I mutation, was 40%, but the mean age of the nonpenetrant mutation carriers is 15, while the mean age of the penetrant mutation carriers is 47. The mutation affects a conserved valine replacing it with a larger isoleucine residue in the region of contact between the light chain and the myosin lever arm. In conclusion, MYL3 mutations can present with low expressivity and late onset.
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2012) conducted an observational in Hypertrophic cardiomyopathy (n=310). MYL3 p.V79I mutation vs. Healthy controls was evaluated on Penetrance of hypertrophic cardiomyopathy phenotype. A novel MYL3 missense mutation (p.V79I) caused hypertrophic cardiomyopathy with 40% penetrance, presenting with low expressivity and late onset.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: